Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTD-001 in Idiopathic Hypersomnia
NCT03542851Phase 2Unknown
- Sponsor
- Balance Therapeutics, Inc.
- Start
- May 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Pentetrazol in idiopathic hypersomnia (IH) (2 arms), sponsored by Balance Therapeutics, Inc. Primary endpoint: Idiopathic Hypersomnia Symptom Diary. Status: unknown.
02
Drugs
Pentetrazol
03
Conditions
idiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT03542851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542851.